Can-Am HIFU, a Center Offering Cutting Edge Non Invasive Prostate Cancer
Treatment, Grows with Addition of New Partner
CHARLOTTE, N.C. and TORONTO, Aug. 7 /CNW/ -- USHIFU, LLC, the exclusive
distributor of the Sonablate(R) 500 in North America, and its affiliated
partner, Can-Am HIFU are pleased to announce that Sender Herschorn, MD has
joined Can-Am HIFU in Toronto. In addition to joining Can-Am HIFU, Herschorn
was appointed to the USHIFU Medical Advisory Board, whose purpose is to
provide expert opinion and guidance to assist with the growth and adoption of
current and future technologies.
"The addition of Dr. Herschorn further validates the HIFU technology, not
only within Canada, but North America as well. Dr. Herschorn holds one of the
top academic urologic posts in North America and is highly regarded for his
work within the field. He is a tremendous addition to the partnership," said
John Linn, USHIFU Vice President of Finance.
"It is with great pleasure on behalf of Can-Am HIFU, that I announce that
my colleague and friend, Dr. Sender Herschorn has become a treating partner,
said Jack Barkin, MD, Director of Can-Am HIFU and Chief of Urology at Humber
River Regional Hospital, as well as, Assistant Professor of Surgery at
University of Toronto. "Dr. Herschorn is the Professor and Chairman of the
Division of Urology for the University of Toronto, one of the most respected
academic University divisions in North America. In doing this, he is joining
his other academic partners, including myself, Neil Fleshner, MD; Laurence
Klotz, MD; Sidney Radomski, MD and Michael Robinette, MD who have been
performing HIFU in Toronto since March of 2006. We are pleased to have Dr.
Herschorn as our new partner and proud to be the first and largest
Sonablate(R) 500 installation delivering High Intensity Focused Ultrasound
(HIFU) for the treatment of prostate cancer in North America."
For additional information on Can-Am HIFU, visit
www.internationalhifu.com, www.can-amhifu.com or call 1-877-787-5906.
HIFU, which stands for High Intensity Focused Ultrasound, utilizes
focused sound waves to rapidly raise the temperature in a targeted area, thus
destroying the tissue in a matter of seconds. This type of acoustic ablation
is delivered through a transrectal probe that allows the physician to perform
HIFU without having to make a single incision.
In Canada, where HIFU is available, the treatment is a one-time,
outpatient procedure. It has also been used in Canada as a salvage therapy
for patients who have had other treatments and have not been satisfied with
The Sonablate(R) 500, approved for use in Canada since June 2005, is
being used in clinical trials in the United States and has not been approved
for U.S. marketing by the FDA. An application to obtain marketing approval in
the U.S. will be submitted to the FDA at the conclusion of these clinical
The Sonablate(R) 500, developed by Focus Surgery Inc., of Indianapolis,
IN, and manufactured by Misonix, Inc., of Farmingdale, NY is the only HIFU
device in Canada that does not require a preliminary transurethral resection
of the prostate (TURP) surgical procedure.
For further information:
For further information: Amanda Willis of USHIFU, LLC, +1-704-332-4308
Web Site: http://www.can-amhifu.com